Cargando…
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
BACKGROUND: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexate (HD-MTX), high-dose AraC (HD-AraC), thiotepa and...
Autores principales: | Wendler, Julia, Fox, Christopher P., Valk, Elke, Steinheber, Cora, Fricker, Heidi, Isbell, Lisa K., Neumaier, Simone, Okosun, Jessica, Scherer, Florian, Ihorst, Gabriele, Cwynarski, Kate, Schorb, Elisabeth, Illerhaus, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464101/ https://www.ncbi.nlm.nih.gov/pubmed/36088292 http://dx.doi.org/10.1186/s12885-022-09723-w |
Ejemplares similares
-
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
por: Schorb, Elisabeth, et al.
Publicado: (2019) -
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial
por: Isbell, Lisa K, et al.
Publicado: (2023) -
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)
por: Schorb, Elisabeth, et al.
Publicado: (2016) -
Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
por: Schorb, Elisabeth, et al.
Publicado: (2021) -
Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors
por: Downs, Bradley M., et al.
Publicado: (2021)